CTI BioPharma Corp.

CTI BioPharma Corp.verified

CTIC

Price:

$9.095

Market Cap:

$1.20B

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.[Read more]

Industry

Biotechnology

IPO Date

1997-03-21

Stock Exchange

NASDAQ

Ticker

CTIC

The PE Ratio as of June 2024 (TTM) for CTI BioPharma Corp. (CTIC) is -16.84

According to CTI BioPharma Corp.’s latest financial reports and current stock price. The company's current PE Ratio is -16.84. This represents a change of 86.07% compared to the average of -9.05 of the last 4 quarters.

CTI BioPharma Corp. (CTIC) Historical PE Ratio (quarterly & annually)

How has CTIC PE Ratio performed in the past?

The mean historical PE Ratio of CTI BioPharma Corp. over the last ten years is -3.40. The current -16.84 PE Ratio has changed 49.37% with respect to the historical average. Over the past ten years (40 quarters), CTIC's PE Ratio was at its highest in in the September 2014 quarter at 19.08. The PE Ratio was at its lowest in in the March 2018 quarter at -12.20.

Quarterly (TTM)
Annual

Average

-3.40

Median

-2.65

Minimum

-7.57

Maximum

-1.40

CTI BioPharma Corp. (CTIC) PE Ratio by Quarter and Year

Discovering the peaks and valleys of CTI BioPharma Corp. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 584.60%

Maximum Annual PE Ratio = -1.40

Minimum Annual Increase = -48.15%

Minimum Annual PE Ratio = -7.57

Quarterly (TTM)
Annual
YearPE RatioChange
2022-7.57237.55%
2021-2.24-48.15%
2020-4.3399.86%
2019-2.1654.29%
2018-1.40-41.58%
2017-2.409.65%
2016-2.19-24.17%
2015-2.89-23.06%
2014-3.75-26.43%
2013-5.10584.60%

CTI BioPharma Corp. (CTIC) Average PE Ratio

How has CTIC PE Ratio performed in the past?

The current PE Ratio of CTI BioPharma Corp. (CTIC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-4.71

5-year avg

-3.54

10-year avg

-3.40

CTI BioPharma Corp. (CTIC) PE Ratio vs. Peers

How is CTIC’s PE Ratio compared to its peers?

CTI BioPharma Corp.’s PE Ratio is less than Rigel Pharmaceuticals, Inc. (-8.41), less than Fortress Biotech, Inc. (-0.53), less than Reviva Pharmaceuticals Holdings, Inc. (-0.80), less than Ocuphire Pharma, Inc. (-3.43), less than Protalix BioTherapeutics, Inc. (12.48), less than Seres Therapeutics, Inc. (-1.37), less than Cidara Therapeutics, Inc. (-1.45), less than ImmunityBio, Inc. (-8.13), less than Galera Therapeutics, Inc. (-0.10), less than Selecta Biosciences, Inc. (-3.39), less than Paratek Pharmaceuticals, Inc. (-3.05), less than Corvus Pharmaceuticals, Inc. (-3.51), greater than Immutep Limited (-80.80), less than Icosavax, Inc. (-8.27), less than Verastem, Inc. (-0.80), greater than ImmunoGen, Inc. (-122.93), less than Intercept Pharmaceuticals, Inc. (-13.55), less than Elevation Oncology, Inc. (-3.08), greater than Viking Therapeutics, Inc. (-58.22), less than TG Therapeutics, Inc. (62.64), less than X4 Pharmaceuticals, Inc. (-1.57), less than PDS Biotechnology Corporation (-2.09), less than Madrigal Pharmaceuticals, Inc. (-12.53),

Build a custom stock screener for CTI BioPharma Corp. (CTIC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CTI BioPharma Corp. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CTI BioPharma Corp. (CTIC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CTI BioPharma Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is CTI BioPharma Corp.'s PE Ratio?

How is the PE Ratio calculated for CTI BioPharma Corp. (CTIC)?

What is the highest PE Ratio for CTI BioPharma Corp. (CTIC)?

What is the 3-year average PE Ratio for CTI BioPharma Corp. (CTIC)?

What is the 5-year average PE Ratio for CTI BioPharma Corp. (CTIC)?

How does the current PE Ratio for CTI BioPharma Corp. (CTIC) compare to its historical average?